Video: Hillary Clinton Praises TPP As “Gold Standard In Free Trade Agreements”

Who are you going to believe, Hillary Clinton or your lying eyes.

Nobody really believes Hillary's TPP flip-flop...

If they have two brain cells to rub together, nobody believes anything Hillary says.

Via NY Post:

Hillary Clinton revealed on Wednesday that she opposes the Trans-Pacific Partnership trade deal, providing just the latest evidence that she is little more than political ambition wrapped in a pantsuit.
Pay attention to the press coverage, because it’s fascinating: Nobody takes Clinton at her word. I’m not just referring to her conservative critics.
Slate’s Jim Newell asks, “Will anyone find Clinton’s position convincing?” The question is purely rhetorical.
The article is headlined “Hillary Clinton Comes Out Against TPP, at Least Until the Democratic Convention.”
In “First Read,” a newsletter put out by “Meet the Press” host Chuck Todd and his colleagues, the lead item on Thursday was titled “Why Clinton’s Trade Flip-Flop Is So Unbelievable.” They write:
“Yes, Hillary Clinton’s new opposition to the Trans-Pacific Partnership trade accord cleans up something she needed to do before next week’s first Democratic debate. And, yes, it puts pressure on Vice President Joe Biden getting into the race (because he’d be on the only major candidate in support of TPP). But make no mistake: This flip-flop isn’t believable at all.”
Keep on reading…

Secret Global Trade Pact Could Limit Access To Generic Drugs...

Republicans have to pass it so you can know what is in it...

Via NY Times:

Mark Grayson, a spokesman for the Pharmaceutical Research and Manufacturers of America, an industry trade group, said that the group was hopeful “that the House will pass the bill so it can get to the president’s desk.”

He declined to comment on the group’s position on the overall pact, saying it was still being negotiated. But he made clear that the pharmaceutical industry was hoping for what he called “strong” intellectual property provisions to be included in the trade pact.

He dismissed concerns that the pact could limit access to generic drugs, noting that the overwhelming majority of prescriptions filled in the United States were for generic medications, despite strong intellectual property laws in this country.

Generic drug industry officials hailed the vote, however.

Heather Bresch, the chief executive of Mylan, a generic drug maker, applauded the defeat on Friday by the House, saying it would give her more time to lobby against the trade pact.

She and other leaders in the generic drug industry have argued that the pact goes too far in protecting the patents of the brand-name drug industry and would block access to generic drugs around the world.

“I think it’s scary and dangerous that the president is looking for this kind of authority on a trade bill that I think has serious flaws in it,” she said. “It’s setting the global generic industry back 30 years.” Read more here...